nominally significantP = 0.0053
Iptacopan improved the eGFR slope by +10.7 mL/min/1.73 m 2 /year compared with pretreatment decline ( P = 0.0057) and also led to a nominally significant reduction in glomerular C3 deposition (mean difference: –1.875; P = 0.0053). 66 In a study evaluating early access use of iptacopan (200 mg twice daily) in 16 patients with recurrent C3G after kidney transplantation, iptacopan was associated with potential stabilization of kidney function.